Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 20/20 | 1.00 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.81 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.81 |
| ▸ | CSF1R | P07333 | 1/20 | 0.81 |
| ▸ | AXL | P30530 | 1/20 | 0.81 |
| ▸ | FLT3 | P36888 | 1/20 | 0.81 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.81 |
| ▸ | MAP3K10 | Q02779 | 1/20 | 0.81 |
| ▸ | DMPK | Q09013 | 1/20 | 0.81 |
| ▸ | EPHA7 | Q15375 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17388010 | 1.00 | MAP3K12 (1.00) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL19921658 | 1.00 | MAP3K12 (1.00) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL17388014 | 1.00 | MAP3K12 (1.00) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL17388053 | 0.90 | MAP3K12 (1.00) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL15889987 | 0.90 | MAP3K12 (1.00) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL17388052 | 0.90 | MAP3K12 (1.00) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL29728248 | 0.90 | MAP3K12 (1.00) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL19921666 | 0.90 | MAP3K12 (1.00) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL19921686 | 0.89 | MAP3K12 (1.00) | MAP3K12MAP3K13NTRK1CSF1RAXL | |
| SCHEMBL17388084 | 0.89 | MAP3K12 (1.00) | MAP3K12MAP3K13NTRK1CSF1RAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | claimed |
| EP-2945938-B1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-03-07 | — | — | EP | claimed |
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | claimed |
| US-9550777-B2 | 3-substituted pyrazoles and use as DLK inhibitors | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | claimed |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2945938-B1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-03-07 | — | — | EP | disclosed |
| EP-2945938-B1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-03-07 | — | — | EP | disclosed |
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9550777-B2 | 3-substituted pyrazoles and use as DLK inhibitors | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550777-B2 | 3-substituted pyrazoles and use as DLK inhibitors | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550777-B2 | 3-substituted pyrazoles and use as DLK inhibitors | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | PDXK, NLK, PDK3 | MAP3K12 128/4885MAP3K13 101/4885NTRK1 670/4885 |
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | PDXK, NLK, PDK3 | MAP3K12 235/4885MAP3K13 195/4885NTRK1 702/4885 |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | PDXK, NLK, PDK3 | MAP3K12 235/4885MAP3K13 195/4885NTRK1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.